Cargando…

Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer

PURPOSE: The presence of extensive ductal carcinoma in situ (DCIS) adjacent to HER2-positive invasive breast cancer (IBC) is often a contra-indication for breast-conserving surgery, even in case of excellent treatment response of the invasive component. Data on the response of DCIS to neoadjuvant sy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Groen, Emma J., van der Noordaa, Marieke E. M., Schaapveld, Michael, Sonke, Gabe S., Mann, Ritse M., van Ramshorst, Mette S., Lips, Esther H., Vrancken Peeters, Marie-Jeanne T. F. D., van Duijnhoven, Frederieke H., Wesseling, Jelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Epidemiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8302531/ https://www.ncbi.nlm.nih.gov/pubmed/33945043 http://dx.doi.org/10.1007/s10549-021-06235-2

Ejemplares similares

Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival
por: van der Voort, Anna, et al.
Publicado: (2022)

Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol
por: van Loevezijn, Ariane A., et al.
Publicado: (2022)

Additional value of (18)F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer
por: van Ramshorst, Mette S., et al.
Publicado: (2017)

Minimally Invasive Complete Response Assessment of the Breast After Neoadjuvant Systemic Therapy for Early Breast Cancer (MICRA trial): Interim Analysis of a Multicenter Observational Cohort Study
por: van Loevezijn, Ariane A., et al.
Publicado: (2020)

[(18)F]FDG-PET/CT in prone compared to supine position for optimal axillary staging and treatment in clinically node-positive breast cancer patients with neoadjuvant systemic therapy
por: van Loevezijn, Ariane A., et al.
Publicado: (2021)

ASO Author Reflections: The Pursuit of Eliminating Surgery after Neoadjuvant Systemic Therapy in Breast Cancer Patients
por: van Loevezijn, Ariane A., et al.
Publicado: (2020)

Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer
por: Rigter, L S, et al.
Publicado: (2013)

Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast
por: van Seijen, Maartje, et al.
Publicado: (2021)

ASO Author Reflections: Biopsy Guided Pathological Response Assessment in Breast Cancer is Insufficient: Additional Pathology Findings of the MICRA Trial
por: van Hemert, Annemiek K. E., et al.
Publicado: (2023)

BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer
por: Liefaard, M. C., et al.
Publicado: (2023)

This house believes that: MARI/TAD is better than sentinel node biopsy after PST for cN+ patients
por: van Hemert, Annemiek K.E., et al.
Publicado: (2023)

Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer
por: Loo, Claudette E., et al.
Publicado: (2016)

Deep (phospho)proteomics profiling of pre- treatment needle biopsies identifies signatures of treatment resistance in HER2(+) breast cancer
por: Debets, Donna O., et al.
Publicado: (2023)

Biopsy-Guided Pathological Response Assessment in Breast Cancer is Insufficient: Additional Pathology Findings of the MICRA Trial
por: van Hemert, Annemiek K. E., et al.
Publicado: (2023)

Influence of neoadjuvant chemotherapy on diffuse reflectance spectra of tissue in breast surgery specimens
por: de Boer, Lisanne L., et al.
Publicado: (2019)

Reliability of preoperative breast biopsies showing ductal carcinoma in situ and implications for non-operative treatment: a cohort study
por: Mannu, Gurdeep S., et al.
Publicado: (2019)

Monitoring tumor response to neoadjuvant chemotherapy using MRI and (18)F-FDG PET/CT in breast cancer subtypes
por: Schmitz, Alexander M. Th., et al.
Publicado: (2017)

Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer
por: Steenbruggen, Tessa G, et al.
Publicado: (2021)

Optical tissue measurements of invasive carcinoma and ductal carcinoma in situ for surgical guidance
por: de Boer, Lisanne L., et al.
Publicado: (2021)

Cause-specific Mortality in a Population-based Cohort of 9799 Women Treated for Ductal Carcinoma In Situ
por: Elshof, Lotte E., et al.
Publicado: (2018)

Tumour-educated platelets for breast cancer detection: biological and technical insights
por: Liefaard, Marte C., et al.
Publicado: (2023)

Correction To: Tumour-educated platelets for breast cancer detection: biological and technical insights
por: Liefaard, Marte C., et al.
Publicado: (2023)

Survival and prognostic factors in oligometastatic breast cancer
por: van Ommen-Nijhof, Annemiek, et al.
Publicado: (2022)

Variability in grading of ductal carcinoma in situ among an international group of pathologists
por: van Seijen, Maartje, et al.
Publicado: (2021)

Prediction Models and Decision Aids for Women with Ductal Carcinoma In Situ: A Systematic Literature Review
por: Schmitz, Renée S. J. M., et al.
Publicado: (2022)

The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort study
por: Elshof, Lotte E., et al.
Publicado: (2017)

Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women
por: Elshof, Lotte E., et al.
Publicado: (2016)

Ductal carcinoma in situ: to treat or not to treat, that is the question
por: van Seijen, Maartje, et al.
Publicado: (2019)

The impact of patient characteristics and lifestyle factors on the risk of an ipsilateral event after a primary DCIS: A systematic review
por: Alaeikhanehshir, Sena, et al.
Publicado: (2020)

Toward Intraoperative Margin Assessment Using a Deep Learning-Based Approach for Automatic Tumor Segmentation in Breast Lumpectomy Ultrasound Images
por: Veluponnar, Dinusha, et al.
Publicado: (2023)

Treating (low-risk) DCIS patients: What can we learn from real-world cancer registry evidence?
por: Byng, Danalyn, et al.
Publicado: (2021)

Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ
por: Almekinders, Mathilde M. M., et al.
Publicado: (2021)

Active surveillance versus treatment in low-risk DCIS: Women’s preferences in the LORD-trial
por: Schmitz, Renée S.J.M., et al.
Publicado: (2023)

Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance
por: Hoogstraat, Marlous, et al.
Publicado: (2022)

Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplification
por: Van Bockstal, Mieke R., et al.
Publicado: (2020)

The Relevance of Breast Cancer Subtypes in the Outcome of Neoadjuvant Chemotherapy
por: Straver, M. E., et al.
Publicado: (2010)

Preferences of Treatment Strategies among Women with Low-Risk DCIS and Oncologists
por: Byng, Danalyn, et al.
Publicado: (2021)

Pathological and Biological Differences Between Screen-Detected and Interval Ductal Carcinoma in situ of the Breast
por: de Roos, Marnix A., et al.
Publicado: (2007)

Prognostic value of breast MRI characteristics before and during neoadjuvant endocrine therapy in patients with ER+/HER2- breast cancer
por: Ragusi, Max AA, et al.
Publicado: (2021)

Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer
por: Dackus, Gwen M. H. E., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rsmmcfut24gbb4oud38ra1ekhs